It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Major depressive disorder ranks as a major burden of disease worldwide, yet the current antidepressant medications are limited by frequent non-responsiveness and significant side effects. The lateral septum (LS) is thought to control of depression, however, the cellular and circuit substrates are largely unknown. Here, we identified a subpopulation of LS GABAergic adenosine A2A receptors (A2AR)-positive neurons mediating depressive symptoms via direct projects to the lateral habenula (LHb) and the dorsomedial hypothalamus (DMH). Activation of A2AR in the LS augmented the spiking frequency of A2AR-positive neurons leading to a decreased activation of surrounding neurons and the bi-directional manipulation of LS-A2AR activity demonstrated that LS-A2ARs are necessary and sufficient to trigger depressive phenotypes. Thus, the optogenetic modulation (stimulation or inhibition) of LS-A2AR-positive neuronal activity or LS-A2AR-positive neurons projection terminals to the LHb or DMH, phenocopied depressive behaviors. Moreover, A2AR are upregulated in the LS in two male mouse models of repeated stress-induced depression. This identification that aberrantly increased A2AR signaling in the LS is a critical upstream regulator of repeated stress-induced depressive-like behaviors provides a neurophysiological and circuit-based justification of the antidepressant potential of A2AR antagonists, prompting their clinical translation.
The mechanism underlying caffeine consumption inversely correlation with depression is unclear. Here, authors identified adenosine A2A receptor in the lateral septum mediating depressive symptoms via direct outputs to the habenula and the hypothalamus.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Wenzhou Medical University, The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou, China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990)
2 The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Department of Neurology, Wenzhou, China (GRID:grid.417384.d) (ISNI:0000 0004 1764 2632); Key Laboratory of Structural Malformations in Children of Zhejiang Province, Wenzhou, China (GRID:grid.417384.d)
3 University of Coimbra, Faculty of Medicine, Coimbra, Portugal (GRID:grid.8051.c) (ISNI:0000 0000 9511 4342); Portuguese National Institute of Legal Medicine and Forensic Sciences (INMLCF, IP), Coimbra, Portugal (GRID:grid.435177.3) (ISNI:0000 0004 0632 8410)
4 Ministry of Education, Naval Medical University, Department of Neurobiology, Key Laboratory of Molecular Neurobiology, Shanghai, China (GRID:grid.73113.37) (ISNI:0000 0004 0369 1660)
5 University of Coimbra, Faculty of Medicine, Coimbra, Portugal (GRID:grid.8051.c) (ISNI:0000 0000 9511 4342); University of Coimbra, CNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal (GRID:grid.8051.c) (ISNI:0000 0000 9511 4342)
6 Wenzhou Medical University, The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou, China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990); Oujiang Laboratory (Zhejiang Laboratory for Regenerative Medicine, Vision and Brain Health), School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990)